Targeted therapy and precision medicine in advanced non-small cell lung cancer: biomarker-driven treatment selection.
Expanding knowledge of cancer-driving genetic mutations enables more precise matching of patients to targeted therapies.
This paper addresses biomarker-driven treatment selection in advanced non-small cell lung cancer. It covers the expanding landscape of actionable genomic targets and corresponding targeted therapies.
What the study was
- Population
- Advanced NSCLC patients
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
Why it surfaced
Standard precision oncology topic. Limited metadata.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.